NAS:NLSP (Switzerland)
Â
Ordinary Shares
$
0.14
+0.00495 (+3.62%)
10:09 PM EST
Business Description
NLS Pharmaceutics Ltd
NAICS : 325199
ISIN : CH0523961370
Share Class Description:
NLSP: Ordinary SharesDescription
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -1.89 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.4 | |||||
| 3-Year EPS without NRI Growth Rate | -22.5 | |||||
| 3-Year FCF Growth Rate | -253.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.35 | |||||
| 9-Day RSI | 38.17 | |||||
| 14-Day RSI | 31.61 | |||||
| 6-1 Month Momentum % | -73.91 | |||||
| 12-1 Month Momentum % | -86.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.58 | |||||
| Quick Ratio | 0.58 | |||||
| Cash Ratio | 0.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.2 | |||||
| Shareholder Yield % | -122.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -862.99 | |||||
| ROA % | -341.08 | |||||
| ROIC % | -3045.22 | |||||
| ROC (Joel Greenblatt) % | -85422.22 | |||||
| ROCE % | -1567.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.32 | |||||
| EV-to-EBITDA | -0.32 | |||||
| EV-to-Forward-Revenue | 64.6 | |||||
| EV-to-FCF | -0.36 | |||||
| Earnings Yield (Greenblatt) % | -312.5 | |||||
| FCF Yield % | -220.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NLSP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NLS Pharmaceutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.5 | ||
| Beta | -1.01 | ||
| Volatility % | 83.51 | ||
| 14-Day RSI | 31.61 | ||
| 14-Day ATR ($) | 0.024411 | ||
| 20-Day SMA ($) | 0.143923 | ||
| 12-1 Month Momentum % | -86.47 | ||
| 52-Week Range ($) | 0.113 - 1.53 | ||
| Shares Outstanding (Mil) | 43.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NLS Pharmaceutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NLS Pharmaceutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NLS Pharmaceutics Ltd Frequently Asked Questions
What is NLS Pharmaceutics Ltd(NLSP)'s stock price today?
The current price of NLSP is $0.14. The 52 week high of NLSP is $1.53 and 52 week low is $0.11.
When is next earnings date of NLS Pharmaceutics Ltd(NLSP)?
The next earnings date of NLS Pharmaceutics Ltd(NLSP) is 2024-07-10 Est..
Does NLS Pharmaceutics Ltd(NLSP) pay dividends? If so, how much?
NLS Pharmaceutics Ltd(NLSP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers